Pelvic External Combined With 252-Cf Neutron Intracavitary Radiotherapy With or Without Platinum in Treating Advanced Cervical Cancer

Launched by DAPING HOSPITAL AND THE RESEARCH INSTITUTE OF SURGERY OF THE THIRD MILITARY MEDICAL UNIVERSITY · Jul 13, 2016

Keywords

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. To be aged from 18 (including 18) to 65 (including 65), female patient;
• • 2. Expected survival ≥6 months
• • 3. Pathologically proven diagnosis of squamous carcinoma or adenocarcinoma of the cervix, according to FIGO(International Federation of Gynecology and Obstetrics) staging, appropriate stage for protocol entry, including IIA2, IIB,IIIA,IIIB;
• • 4. No patients with distant metastases;
• • 5. Measurable target lesions (satisfying the criteria in RECIST 1.1);
• • 6. ECOG PS status of 0-2;
• • 7. No prior treatment;
• • 8. No
• • 9. No surgery
• * 10. Major organ function has to meet the following criteria:
• • 1. Bilirubin \<1.5 times the upper limit of normal (ULN)
• • 2. ALT , AST and APL≤2.5 × ULN
• • 3. NEUT≥2.0 × 10\^9 / L
• • 4. PLT ≥ 100 × 10\^9 / L
• • 5. HB≥60g/L
• • 6. Serum Cr and urea nitrogen ≤ 1.5 × ULN
• • 11. Favorable cardiac functions, no patients with myocardial infarction within half a year, hypertension and coronary disease are well-controlled.
• Exclusion Criteria:
• • 1. Serious heart disease, pulmonary disease, hepatic disease, , renal disease and metabolic disease, or with electrolyte disturbance;
• • 2. Allergic to platinum;
• • 3. Rejecte to join the study in other conditions.